You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 207691 - 207700 of 207731 results
  1. Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass

    SBC: OMNIOX INC            Topic: NICHD

    1. PROJECT SUMMARY/ABSTRACT Omniox is developing a unique oxygen delivery protein, OMX, as a treatment to preserve myocardial and peripheral organ function and significantly reduce morbidity after neonatal cardiopulmonary bypass (CPB) during surgical correction of congenital heart disease (CHD). Of the ~40,000 children born annually with CHD, ~10,000 require urgent surgery to repair heart defects1 ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Clinic-Ready MACH-1 Gene Gun for delivery of a universal influenza DNA vaccine

    SBC: ORLANCE, INC            Topic: NIAID

    PROJECT SUMMARY Orlance has developed a lead universal influenza (UFlu) DNA vaccine to address the need for a vaccine that can protect from annual influenza and the emergence of new variants that could cause future pandemics. Our UFlu vaccine is a multi-dose vaccine designed to induce systemic and mucosal immune responses that can prevent transmission and minimize disease from currently circulatin ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Boron-containing antimalarial drug discovery

    SBC: REACTIVE BIOSCIENCES INC            Topic: NIAID

    PROJECT SUMMARY New drugs to treat malaria, ideally with unique chemical structures and mechanisms of action, are urgently needed. Optimal drug candidates for the treatment and prevention of malaria will have potent activity against cultured parasites and in animal models of malaria, be rapidly active against erythrocytic malaria parasites, be orally bioavailable, have extended pharmacological exp ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid response to pandemic influenza via multi-antigen RNA-based vaccine

    SBC: TIBA BIOTECH LLC            Topic: NIAID

    Project Abstract Avian influenza A H7N9 causes severe respiratory illness with a high mortality rate, and its zoonotic capacity has raised serious concerns over the possibility of a pandemic. The value of vaccines for pandemic-potential viruses has been demonstrated by the devastating effects of COVID-19 on human health and the economy. Development of H7 Influenza vaccines has lagged, as pandemic ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Biomarker-Based Test of Cure for Chagas Disease

    SBC: KEPHERA DIAGNOSTICS LLC            Topic: NIAID

    Project Summary Chagas disease, caused by infection with Trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, infecting 8-11 million individuals and with over 70 million at risk. The infection is transmitted by an insect vector, but can also be acquired through blood transfusion, organ transplant, or congenitally. Following a brief acute phase, the parasite persist ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Using Structured Light Sensing with Machine Learning to Detect Unwitnessed In-Home Falls

    SBC: APPLIED UNIVERSAL DYNAMICS, CORP            Topic: NIA

    Project Summary/Abstract Older adults are disproportionately affected by falls. Older adults who have memory loss (mild to moderate cognitive impairment) can forget to wear wireless alert pendants or wristbands that are used in case they fall in their home. Falls among adults 65 and older caused over 34,000 deaths in 2019, making it the leading cause of injury death for that group. Older adult fal ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy

    SBC: IllExcor Therapeutics LLC            Topic: NHLBI

    Sickle Cell Disease (SCD) affects ~100,000 individuals in the US and millions more worldwide. The disease causes a range of adverse pathophysiological effects resulting in painful crises, organ failure, and eventually, premature death. Our scientists spearheaded the development of a novel class of oral anti-sickling drugs based on natural aromatic aldehydes, like vanillin from vanilla extract. Thi ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Novel therapy for alcoholic liver disease-associated hepatorenal syndrome

    SBC: MITOPOWER LLC            Topic: 999

    Novel therapy for alcoholic liver disease-associated hepatorenal syndrome Abstract Alcoholic liver disease (ALD) results in over 400,000 hospitalizations each year in the US, with a portion of these patients developing hepatorenal syndrome with acute kidney injury (HRS-AKI). There are no current therapeutic options that specifically address the cellular dysfunction and systemic inflammatory respon ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Commercialization of an Improved Treatment of Extremity Fractures Using a Regenerative Bone Adhesive to Accelerate Bone Healing in Aging Patients

    SBC: REVBIO, INC.            Topic: NIA

    Project Abstract/Summary In the U.S., about 2.1 million people experience a fragility fracture each year. This number is expected to double or triple by 2040 as the population ages. Injuries in the upper and lower extremities equate to more than 40% of fragility fractures, and experiencing a prior fracture is associated with an 86% increased risk of recurrence. Falls from standing height and other ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government